
Chicago-based accelerator for technology companies serving the real estate industry

Connecticut and London venture capital firm backing science-led life sciences and IT companies

New Science Ventures invests in life sciences companies whose work is at clinical stage. Novadip Biosciences is developing regenerative tissue products intended to speed the healing of large bone defects. NorthSea Therapeutics is developing structurally engineered fatty acids for non-alcoholic steatohepatitis and other metabolic diseases. Ventyx Biosciences focuses on oral therapies for inflammatory diseases, and Resolve Therapeutics is developing targeted therapies for autoimmune conditions.
Cambridge Epigenetix describes itself as a life sciences tools and technology company working on genome sequencing. VUV Analytics makes the LUMA multi-channel vacuum ultraviolet absorbance detector, which the company says fits into existing laboratory workflows and offers best-in-class sensitivity. Holdings like these show the firm's interest in the tools scientists use every day, as well as in therapies.
The portfolio reaches into space as well. Phase Four builds radio-frequency thrusters for satellites and has described a plasma propulsion line for satellite manufacturers. The firm also invests in information technology companies that use novel science, and it describes its criteria as the same across life sciences and technology. Its stated focus is on significant unmet needs, which it treats as the test for any investment.
Cambridge Epigenetix's tools are aimed at genome sequencing, and Novadip's products at regenerating tissue damaged by injury or disease. NorthSea's work centres on structurally engineered fatty acids for liver conditions linked to metabolism. Ventyx is developing an oral TYK2 inhibitor for inflammatory conditions, and Resolve Therapeutics is aiming at underserved autoimmune diseases with first-in-class therapies. VUV Analytics's LUMA detector is designed to integrate into existing laboratory work, which the company says it does with best-in-class sensitivity. Phase Four's propulsion work centers on radio-frequency thrusters that could give satellite makers a higher performance engine.
New Science Ventures, or NSV, is a venture capital firm based in Connecticut and London. It invests in companies that use new scientific approaches, both at early and later stages, in life sciences and information technology.
Companies that address significant unmet needs in life sciences and information technology through novel science.
Summary written by TrustList from the business's own published information, Oct 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about New Science Ventures.
Similar listings buyers compare against this one.

Chicago-based accelerator for technology companies serving the real estate industry

Semiconductor and display equipment maker that also invests in startups through venture and research programmes

Semiconductor and sensing company selling components and design tools to engineers in industrial, automotive and healthcare markets

Global startup accelerator and early-stage investor running city and sector programmes for founders

Venture arm of a crypto exchange investing in early-stage web3 and blockchain startups

Global software investor backing growth-stage technology companies with capital and in-house operating specialists

Venture capital firm linked to NTT that backs start-up founders through partnerships

Global aerospace accelerator and investor supporting start-ups from formation to acquisition
Everything here links back to the same verified catalogue. Pick your next stop.